Shanghai Henlius Biotech, Inc. (2696.HK)

22.600 +0.100 (+0.44%) At close: 04:08PM HKT

Shanghai Henlius Biotech, Inc.

Building B8
11th Floor 188 Yizhou Road Xuhui District
Shanghai 200233
China
86 21 3339 5800
https://www.henlius.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 3,637

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Wenjie Zhang	Executive Chairman of the Board	12.53M	N/A	1967
Mr. Jun Zhu	CEO, CFO & Executive Director	9.78M	N/A	1979
Ms. Huang Wei	President	N/A	N/A	1969
Dr. Shi-Kau Liu	Co-founder & Head of Strategy Advisory Committee	6.68M	N/A	1964
Dr. Wei-Dong Jiang	Co-Founder & Co-Head of Innovative Advisory Committee	N/A	N/A	1963
Dr. Jifeng Zhang	CTO & Senior VP	N/A	N/A	1971
Ms. Miaojie Chen	Vice President of Legal & Compliance Department	N/A	N/A	N/A
Mr. Wallis Zeng	VP of Sales & Oncology Business Unit	N/A	N/A	N/A
Ms. Junhua Li	VP & Chief Human Resource Officer	N/A	N/A	1977
Mr. Xinjun Guo	Senior Vice President	N/A	N/A	1973

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and recurrent non-small cell lung cancer; and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. The company also develops Serplulimab to treat squamous-cell carcinomas, gastric cancer, small cell lung cancer, hepatocellular carcinoma, metastatic colorectal cancer, solid tumors, SCCHN, sqNSCLC, hepatocellular carcinoma, and esophageal squamous cell carcinoma; HLX04-O, an anti-VEGF monoclonal antibody injection for wet age-related macular degeneration; HLX22 to treat breast and metastatic gastric cancer; HLX6018 to treat idiopathic pulmonary fibrosis; HLX07, HLX22, HLX208, HLX60, HLX42, HLX43, HLX53, and HLX51 to treat solid tumors; HLX11 to treat breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; and HLX14 to treat osteoporosis. In addition, it develops HLX26 for the treatment of solid tumor and lymphoma; HLX13 to treat melanoma, renal cell carcinoma, and mCRC; and HLX15 for multiple myeloma. The company operates in Mainland China, the Asia Pacific, North and South America, and Europe. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Corporate governance

Shanghai Henlius Biotech, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.